title: [Clinical effect of combined artificial extracorporeal liver support therapy for toxic hepatic failure].
abstract: Objective:To investigate the clinical effect of plasma exchange (PE) versus double plasma molecular adsorption system combined with PE (DPMAS+PE) in the treatment of toxic hepatic failure.Methods:A total of 67 patients with toxic hepatic failure who were admitted during the same period of time were divided into PE group, DPMAS+ PE group, and control group. The 22 patients in the PE group were treated with PE alone, and the 24 patients in the DPMAS+PE group were given DPMAS combined with PE. The clinical out-come was compared between the three groups.Results:Both treatment groups had significantly higher clinical response rate and 24-week survival rate than the control group. After treatment, both treatment groups had significant reductions in the serum levels of total bilirubin (TBil) , direct bilirubin (DBil) , alanine aminotransfer-ase (ALT) , and aspartate aminotransferase (AST) , and the PE group had significant reductions in the albumin (Alb) level and activated partial thromboplastin time (APTT) (P<0.05) ; the DPMAS+PE group showed no sig-nificant changes in the Alb level and APTT (P>0.05). There were no significant differences in TBil, DBil, ALT, and AST between the two treatment groups after treatment (P>0.05). After treatment, the PE group had significantly higher Alb level and APTT than the DPMAS + PE group (P<0.05). Compared with the control group, both treatment groups had significant reductions in TBil, DBil, ALT and AST after treatment (P<0.05).Conclusion:The two artificial liver support techniques can significantly improve patients' liver function and in-crease their survival rate, and the combined artificial liver support technique can reduce the amount of plasma used.
authors.affiliation: Affiliated hospital of Taishan Medical University; Taian 271000, China.
authors.forename: Y D
authors.initials: YD
authors.lastname: Zhou
authors.forename: L
authors.initials: L
authors.lastname: Yang
authors.forename: Q F
authors.initials: QF
authors.lastname: Han
authors.forename: Q B
authors.initials: QB
authors.lastname: Tang
authors.forename: Y L
authors.initials: YL
authors.lastname: Cheng
authors.forename: J X
authors.initials: JX
authors.lastname: Shi
mesh_terms: D065966:Absorption, Physicochemical; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D002681:China; D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D017093:Liver Failure / Q000401:mortality / Q000628:therapy*; D010951:Plasma Exchange; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin
keywords: Live, artificial; Liver failure; Poison